MRI scans are strong diagnostics with high-definition images of what lies inside a body. Strong magnetic fields require precaution, as brought out by an instance where a young woman suffered very serious injuries due to an oversight in a metallic core within a silicone sex toy that she happened to have before the MRI scan. This makes a stark reminder about the potentially deadly consequences of missing metal objects when such procedures are being performed. In April 2023, a 23-year-old woman went into an MRI with a silicone plug containing a metal core that was not known.
She thought that the item is made entirely out of silicone according to the advertising. However, the strong magnetic field of the MRI machine interacted with the hidden metal, dragging the object through her body and causing excruciating pain. According to reports from the U.S. Food and Drug Administration (FDA), the scene was harrowing, with the woman screaming in agony and requiring immediate hospitalization. Despite pre-scan screenings, which are routine prior to a scan, the patient did not inform the facility that the object existed because he presumed it was purely non-metallic. This caused serious injuries that led to the patient's law suit against the manufacturer for deceitful misrepresentations of material content.
MRI machines employ magnets between 0.5 to 3 Tesla (T). This is thousands of times stronger than the Earth's magnetic field. The tremendous force causes ferromagnetic materials, like iron and nickel, to be magnetized quickly and become strongly attracted toward the magnet. Objects as small as hairpins or paper clips will accelerate at 40 miles per hour inside the magnetic field.
The force can lead to catastrophic injuries in items lodged within the body, such as metallic implants or foreign objects. Metallic cores within devices, like pacemakers or intrauterine devices, must be disclosed to radiologists to prevent such complications.
On these claims, Dr. Adam Taylor, a specialist in human anatomy, weighed his words in a international health website and added that the distance away and mass of this object would increase its velocity towards that of sound, "The acceleration would be phenomenal, but with a metallic core, it can't go anywhere near supersonic speeds. As for the size, the magnetic acceleration to the internal soft tissues would ensure that there could be severe intracranial trauma."
The injuries inflicted in this case likely involved damage to major blood vessels, nerves, or organs, highlighting the devastating impact of even minor oversight during an MRI scan.
This is not an isolated case. There are documented cases of metallic objects causing serious damage during MRI scans with a 65-year-old man with schizophrenia swallowed metal objects, including sockets and a hinge pin. The powerful magnetic field during an MRI scan caused the objects to rupture his stomach, resulting in serious injuries.
A toddler who ingested 11 small magnets perforated his bowel while undergoing a scan, making his case unique. In another deadly but extremely rare incident, there have been people who hide a firearm on themselves during MRI procedures. Magnetic attraction can trigger a discharge in a weapon and has led to some fatal injuries.
These cases emphasize the very strong need for adequate screening and patient education prior to an MRI.
Medical professionals have been trained to avoid risks. This is by properly screening a patient for metallic objects. In general, most pre-scan protocols include:
The case emphasizes the importance of product labeling by manufacturers, especially those products that are likely to unintentionally cause harm to health. The patient's assumption that her device was 100% silicone points to a larger problem in consumer markets with misinformation.
It also reminds the patients to report any possible dangers to the medical professionals, no matter how the objects look non-metallic. In sensitive cases, patients can request private discussions with healthcare providers to ensure safety without discomfort.
In the end, it is a joint effort from manufacturers, healthcare professionals, and patients that can prevent such tragedies. Manufacturers must ensure truthful marketing, while healthcare providers should educate patients about the dangers of metal objects in MRI settings. For patients, understanding the risks and actively participating in pre-scan disclosures can be lifesaving.
This young woman's experience is a sobering example of the unforeseen dangers posed by MRI machines when precautions are overlooked. It serves as a wake-up call to address gaps in patient awareness, medical protocols, and product transparency. By learning from this incident, the medical community and the public can work together to ensure MRI scans remain a safe and effective diagnostic tool.
Credit: AI
The US Food and Drug Administration (FDA) has approved pirtobrutinib as a first-line treatment for adults with previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) who do not have a known deletion of chromosome 17p.
The approval expands the use of the targeted cancer drug, which was previously approved for certain patients whose CLL or SLL had returned or stopped responding to earlier treatment. It is developed by Eli Lilly and Company and will be sold under the brand name Jaypirca.
CLL is a type of blood cancer in which the bone marrow produces too many abnormal B lymphocytes, a type of white blood cell. These abnormal cells can build up in the blood, bone marrow and lymph nodes.
SLL is closely associated with CLL, but the cancer cells are found mainly in the lymph nodes. CLL can progress slowly in some people, while others may develop more aggressive disease.
Pirtobrutinib is a Bruton tyrosine kinase (BTK) inhibitor, a type of targeted therapy. BTK is a protein that helps B cells receive signals needed for their growth and survival. By blocking BTK, pirtobrutinib interferes with signals that cancerous B cells depend on.
Unlike older covalent BTK inhibitors, pirtobrutinib is a non-covalent, reversible BTK inhibitor, meaning it binds to BTK differently.
A dose of 200 mg once a day is recommended for newly diagnosed patients covered by this approval. It should be taken until the cancer progresses or side effects become severe.
Also read: 2 Indians Charged In US Over Fake Ozempic Scheme: How To Spot Counterfeit GLP-1 Drugs
The FDA based its decision on the BRUIN CLL-313 trial, which included 282 adults with previously untreated CLL or SLL without a 17p deletion.
Participants were randomly assigned to receive either pirtobrutinib or the chemotherapy combination bendamustine plus rituximab.
After a median follow-up of 28 months, the median progression-free survival could not yet be calculated for patients receiving pirtobrutinib because enough disease-progressing events had not occurred. In the bendamustine-rituximab group, median progression-free survival was 33.5 months.
The risk of disease progression or death was 80% lower with pirtobrutinib than with bendamustine plus rituximab in the trial, based on the reported hazard ratio of 0.20.
However, overall survival data are still not 100% reliable. There were 13 deaths at the time of the primary analysis - three in the pirtobrutinib group and 10 in the comparison group.
The most common non-laboratory side effects reported with pirtobrutinib included:
According to the FDA, side effects also include infections, bleeding, reduced blood cell counts, abnormal heart rhythms, other cancers, liver toxicity and harm to an unborn baby. Serious adverse reactions occurred in 28% of patients receiving pirtobrutinib in the trial.
The approval gives eligible people with previously untreated CLL or SLL another targeted treatment option that can be taken as a daily oral medicine.
Jennifer A. Woyach, MD, director of the Division of Hematology at The Ohio State University Comprehensive Cancer Center, said, “This approval is grounded in data from BRUIN CLL-313, which showed a significant delay in disease progression for pirtobrutinib compared to chemoimmunotherapy, along with safety and tolerability consistent with its established profile.”
The FDA's decision applies specifically to adults with previously untreated CLL or SLL without a known 17p deletion. It therefore does not mean that pirtobrutinib is automatically the first treatment for every person newly diagnosed with CLL.
Credit: iStock
UK hospitals are seeing an increase in COVID-19 activity as the SARS-CoV-2 XFG variant, dubbed “American Covid” or “Stratus,” circulates in the country.
According to the latest data from the UK Health Security Agency (UKHSA), COVID positivity in hospital settings increased from 5.9% to 7.0%. The weekly hospital admission rate also rose from 0.81 to 1.20 per 100,000, an increase of about 48%.
London recorded the highest increase among regions, with its COVID hospital admission rate rising by 79%.
More than half of the sequenced positive samples were reported to be XFG. Among people aged over 85, hospital admission rates increased from 7.08 to 12.43 per 100,000.
However, the true number of infections could be higher because fewer people are testing for COVID-19 than during the pandemic.
Also read: Flu 2026: Symptoms To Watch For As New Season Begins
XFG is a recombinant SARS-CoV-2 variant formed from Omicron subvariants LF.7 and LP.8.1.2. The WHO records the earliest documented XFG sample on January 27, 2025, and designated it a variant under monitoring in June 2025.
The variant has since been detected in multiple countries and remains among the SARS-CoV-2 variants being monitored by WHO.
COVID symptoms can vary between individuals. Reported symptoms associated with the current circulation of XFG include:
Some people may also experience muscle and joint aches, gastrointestinal symptoms as well as eye or chest infections, while others may have no symptoms.
London GP Dr Renée Hoenderkamp has highlighted symptoms including sore throat, headache, runny nose, fatigue and flu-like aches, Daily Mail reported.
Read More: WHO Sets 2027 Flu Vaccine Strains; US States Can Now Order Free COVID Shots For Kids
There is currently no evidence that the variants circulating in the UK are causing more severe disease.
“There is no evidence that variants currently circulating in the UK are causing more severe disease,” Dr Siggins said. “However, COVID can still cause serious illness in those at greatest risk.”
The latest available figures cited in reports recorded seven deaths involving COVID in England in the week ending August 28, compared with six the previous week.
Older adults and people with underlying conditions remain more vulnerable to severe COVID.
The current increase is not comparable with the waves seen during the height of the COVID pandemic. UKHSA classifies the current hospital admission rate as being at a baseline level.
“COVID is increasing, but from a low level, which is not unexpected at this time of year,” said Dr Matthew Siggins, lecturer in immunity and infection biology at the University of Surrey, according to reports.
WHO has assessed the additional public health risk posed by XFG as low at the global level. Current evidence does not indicate that XFG causes more severe illness or deaths than other circulating variants.
People who develop a high temperature or feel particularly unwell should stay home and avoid contact with others while they recover.
People eligible for the autumn COVID vaccination are advised to get vaccinated to maintain protection against serious illness.
Most people have some immunity from previous infection, vaccination or both. However, immunity may decline over time and does not always prevent infection. Protection against severe disease is generally stronger.
WHO has said currently approved COVID vaccines are expected to continue providing protection against symptomatic and severe disease from XFG.
Credit: PIB
Robotic technology is set to become an accelerating tool across every specialty of medicine, covering diagnostics, treatment and therapy in India, Union Minister of State (Independent Charge) for Science & Technology Dr. Jitendra Singh said.
Speaking at the inaugural session of the International Conference of the Society of Robotic Surgery in New Delhi, Singh said robotics should not be viewed as technology limited to surgery but as a tool that could increasingly be used across different branches of medicine.
“It’s a tool. It will happen everywhere,” he said, adding that the future could see the emergence of robotic medicine, robotic endocrinology and robotic cardiology, just as AI is finding applications across medical specialties.
Singh said robotics, artificial intelligence (AI) and nanoscience could create a larger ecosystem for precision health delivery and precision medicine.
Emerging technologies, he said, could enable increasingly personalized healthcare based on an individual's genetic profile, environmental conditions, lifestyle and dietary patterns.
He said the next phase of medicine could see greater use of genetically driven diagnostics alongside advances in quantum technologies, nanomedicine, AI and robotics.
Singh also expressed a desire to launch gene sequencing for every newborn. Referring to the Genome India Program, he said 10,000 individuals have already been sequenced and that AI and robotics could support detailed genetic sequencing across India's population of 1.4 billion.
He also highlighted the potential of tele-robotics, sharing his experience of performing an ultrasound on a person located 10,000 kilometers away in Antarctica.
The shift toward robotic medicine is already visible in surgery. AIIMS experts recently explained how robotic technology is changing gallbladder surgery, building on the transition from open surgery to laparoscopy and now robotic-assisted procedures.
Professor Hemanga K Bhattacharjee, Department of Surgical Disciplines, AIIMS New Delhi, said inflammation, adhesions, scarring and unexpected anatomy can make gallbladder surgery difficult.
“What the surgeon encounters once the procedure begins can be very different from what was expected. In such situations, robotic-assisted surgery can be an ideal option, as the enhanced visualization and instrument control can help the surgeon navigate difficult anatomy with greater precision,” Bhattacharjee said.
The AIIMS Department of Surgical Disciplines uses the da Vinci robotic system, which provides a high-definition 3D view and wristed instruments for controlled movements. The department has performed more than 1,500 robot-assisted surgeries across specialties, according to hospital authorities.
Dr. Sunil Chumber, Head of the Department of Surgical Disciplines at AIIMS, Delhi, has worked through the evolution from open surgery and mini-laparotomy to laparoscopy and robotic-assisted surgery.
He described robotic-assisted surgery as “a significant step forward” and said he considers it “a superior surgical platform” based on his experience.
“My expectation is that, eventually, gallbladder surgery will be performed robotically and conventional laparoscopy will be phased out,” Chumber said.
“Every generation of surgery builds on what came before it. Laparoscopy was a major advancement in its time, but having worked with robotic-assisted surgery, I believe robotics is the next step in that evolution.”
© $2026 Times Horizon Private Limited